211 related articles for article (PubMed ID: 23894347)
1. Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.
Wang J; Lu K; Song Y; Xie L; Zhao S; Wang Y; Sun W; Liu L; Zhao H; Tang D; Ma W; Pan B; Xuan Q; Liu H; Zhang Q
PLoS One; 2013; 8(7):e68798. PubMed ID: 23894347
[TBL] [Abstract][Full Text] [Related]
2. RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.
Wang J; Lu K; Song Y; Zhao S; Ma W; Xuan Q; Tang D; Zhao H; Liu L; Zhang Q
PLoS One; 2015; 10(7):e0133964. PubMed ID: 26218592
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Ingle JN; Schaid DJ; Goss PE; Liu M; Mushiroda T; Chapman JA; Kubo M; Jenkins GD; Batzler A; Shepherd L; Pater J; Wang L; Ellis MJ; Stearns V; Rohrer DC; Goetz MP; Pritchard KI; Flockhart DA; Nakamura Y; Weinshilboum RM
J Clin Oncol; 2010 Nov; 28(31):4674-82. PubMed ID: 20876420
[TBL] [Abstract][Full Text] [Related]
4. Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Umamaheswaran G; Kadambari D; Muthuvel SK; Kalaivani S; Devi J; Damodaran SE; Pradhan SC; Dubashi B; Dkhar SA; Adithan C
Breast Cancer Res Treat; 2020 Jul; 182(1):147-158. PubMed ID: 32385792
[TBL] [Abstract][Full Text] [Related]
5. Significant role of estrogen and progesterone receptor sequence variants in gallbladder cancer predisposition: a multi-analytical strategy.
Srivastava A; Sharma KL; Srivastava N; Misra S; Mittal B
PLoS One; 2012; 7(7):e40162. PubMed ID: 22808109
[TBL] [Abstract][Full Text] [Related]
6. Association between ESR1 and ESR2 gene polymorphisms and hyperlipidemia in Chinese Han postmenopausal women.
Zhao T; Zhang D; Liu Y; Zhou D; Chen Z; Yang Y; Li S; Yu L; Zhang Z; Feng G; He L; Xu H
J Hum Genet; 2010 Jan; 55(1):50-4. PubMed ID: 19927160
[TBL] [Abstract][Full Text] [Related]
7. The AGT Haplotype of the ESR2 Gene Containing the Polymorphisms rs2077647A, rs4986938G, and rs1256049T Increases the Susceptibility of Unexplained Recurrent Spontaneous Abortion in Women in the Chinese Hui Population.
Tang D; Bao J; Bai G; Hao M; Jin R; Liu F
Med Sci Monit; 2020 May; 26():e921102. PubMed ID: 32359133
[TBL] [Abstract][Full Text] [Related]
8. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
[TBL] [Abstract][Full Text] [Related]
9. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Harvey V; Neven P; Arnould L; Maibach R; Price KN; Coates AS; Goldhirsch A; Gelber RD; Pagani O; Viale G; Rae JM; Regan MM;
Breast Cancer Res Treat; 2015 Dec; 154(3):543-55. PubMed ID: 26590813
[TBL] [Abstract][Full Text] [Related]
10. The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.
Shanmugam VK; McCloskey J; Elston B; Allison SJ; Eng-Wong J
Breast Cancer Res Treat; 2012 Jan; 131(2):699-708. PubMed ID: 22076476
[TBL] [Abstract][Full Text] [Related]
11. New evidence for involvement of ESR1 gene in susceptibility to Chinese migraine.
An X; Fang J; Lin Q; Lu C; Ma Q; Qu H
J Neurol; 2017 Jan; 264(1):81-87. PubMed ID: 27778160
[TBL] [Abstract][Full Text] [Related]
12. Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.
Johansson H; Gray KP; Pagani O; Regan MM; Viale G; Aristarco V; Macis D; Puccio A; Roux S; Maibach R; Colleoni M; Rabaglio M; Price KN; Coates AS; Gelber RD; Goldhirsch A; Kammler R; Bonanni B; Walley BA;
Breast Cancer Res; 2016 Nov; 18(1):110. PubMed ID: 27825388
[TBL] [Abstract][Full Text] [Related]
13. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.
Santa-Maria CA; Bardia A; Blackford AL; Snyder C; Connolly RM; Fetting JH; Hayes DF; Jeter SC; Miller RS; Nguyen A; Quinlan K; Rosner GL; Slater S; Storniolo AM; Wolff AC; Zorzi J; Henry NL; Stearns V
Breast Cancer Res Treat; 2018 Aug; 171(1):121-129. PubMed ID: 29752687
[TBL] [Abstract][Full Text] [Related]
14. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Harvey VJ; Neven P; Treilleux I; Rasmussen BB; Maibach R; Price KN; Coates AS; Goldhirsch A; Pagani O; Viale G; Rae JM; Regan MM
Breast Cancer Res Treat; 2015 Jun; 151(2):373-84. PubMed ID: 25935582
[TBL] [Abstract][Full Text] [Related]
15. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Borrie AE; Rose FA; Choi YH; Perera FE; Read N; Sexton T; Lock M; Vandenberg TA; Hahn K; Younus J; Logan D; Potvin K; Yaremko B; Yu E; Lenehan J; Welch S; Teft WA; Kim RB
Breast Cancer Res Treat; 2020 Sep; 183(2):365-372. PubMed ID: 32632513
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer.
Umamaheswaran G; Kadambari D; Muthuvel SK; Kumar NAN; Dubashi B; Aibor Dkhar S; Adithan C
PLoS One; 2021; 16(3):e0247989. PubMed ID: 33760860
[TBL] [Abstract][Full Text] [Related]
17. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
Fontein DB; Houtsma D; Nortier JW; Baak-Pablo RF; Kranenbarg EM; van der Straaten TR; Putter H; Seynaeve C; Gelderblom H; van de Velde CJ; Guchelaar HJ
Breast Cancer Res Treat; 2014 Apr; 144(3):599-606. PubMed ID: 24590773
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.
Cao A; Zhang J; Liu X; Wu W; Liu Y; Fan Z; Zhang A; Zhou T; Fu P; Wang S; Ouyang Q; Tang J; Jiang H; Zhang X; Pang D; He J; Shi L; Wang X; Sheng Y; Mao D; Shao Z
Health Qual Life Outcomes; 2016 Mar; 14():51. PubMed ID: 27009092
[TBL] [Abstract][Full Text] [Related]
19. Association of rs2234693 and rs9340799 polymorphisms of ESR1 gene in breast cancer of Mexican population.
Carrillo-Moreno DI; Eduardo Figuera L; Zuniga González GM; Puebla Perez AM; Jesus Moran Mendoza A; Gallegos Arreola MP
J BUON; 2019; 24(5):1927-1933. PubMed ID: 31786857
[TBL] [Abstract][Full Text] [Related]
20. The estrogen receptor 1 gene affects bone mineral density and osteoporosis treatment efficiency in Slovak postmenopausal women.
Mondockova V; Adamkovicova M; Lukacova M; Grosskopf B; Babosova R; Galbavy D; Martiniakova M; Omelka R
BMC Med Genet; 2018 Sep; 19(1):174. PubMed ID: 30241506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]